

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.  
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	CARDIEX LIMITED
<b>ABN</b>	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Niall Cairns
<b>Date of last notice</b>	14 May 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<u>C2 Ventures Pty Ltd</u> Niall Cairns is a controller of this entity.  <u>Carnethy Evergreen Pty Ltd</u> Niall Cairns is the controller of this entity.  <u>Carnethy Investments Pty Ltd</u> Niall Cairns is the controller of this entity.
<b>Date of change</b>	27 June 2025

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<p><u>Direct Interests</u></p> <ul style="list-style-type: none"> <li>• 2,000,000 Performance Rights expiring 30 November 2027</li> <li>• 7,500,000 Performance Rights expiring 9 May 2030</li> <li>• 1,000,000 FPO</li> </ul> <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 122,776,955 FPO</li> <li>• 1,500,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026</li> <li>• 32,417,520 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <p><u>Carnethy Evergreen Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 1,937,702 FPO</li> <li>• 200,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026</li> <li>• 475,902 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <p><u>Carnethy Investments Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 8,465,310 FPO</li> <li>• 2,621,771 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul>
<b>Class</b>	As above
<b>Number acquired</b>	<p><u>Direct interests</u></p> <ul style="list-style-type: none"> <li>• 250,000 FPO Shares at \$0.04 per share under the Entitlement Offer</li> </ul> <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 45,694,239 FPO Shares at \$0.04 per share under the Entitlement Offer (including sub-underwriting)</li> </ul> <p><u>Carnethy Evergreen Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 5,146,502 FPO Shares at \$0.04 per share under the Entitlement Offer (including sub-underwriting)</li> </ul> <p><u>Carnethy Investments Pty Ltd</u></p> <ul style="list-style-type: none"> <li>• 2,116,328 FPO Shares at \$0.04 per share under the Entitlement Offer</li> </ul>
<b>Number disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<b>Acquired</b>  All Fully Paid Ordinary Shares were issued for \$0.04 per share cash consideration as per the non-renounceable pro rata Entitlement offer announced to the ASX on 6 June 2025.
<b>No. of securities held after change</b>	<b>Direct Interests</b> <ul style="list-style-type: none"> <li>• 2,000,000 Performance Rights expiring 30 November 2027</li> <li>• 7,500,000 Performance Rights expiring 9 May 2030</li> <li>• 1,250,000 FPO</li> </ul> <b>C2 Ventures Pty Ltd</b> <ul style="list-style-type: none"> <li>• 168,471,194 FPO</li> <li>• 1,500,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026</li> <li>• 32,417,520 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <b>Carnethy Evergreen Pty Ltd</b> <ul style="list-style-type: none"> <li>• 7,084,204 FPO</li> <li>• 200,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026</li> <li>• 475,902 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <b>Carnethy Investments Pty Ltd</b> <ul style="list-style-type: none"> <li>• 10,581,638 FPO</li> <li>• 2,621,771 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<b>Acquired</b> Fully Paid Ordinary Shares issued in accordance with the non-renounceable pro rata Entitlement offer announced to the ASX on 6 June 2025.

+ See chapter 19 for defined terms.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A as no interest in contracts.
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available.  
Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	CARDIEX LIMITED
<b>ABN</b>	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Craig Cooper
<b>Date of last notice</b>	14 May 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	C2 Ventures Pty Ltd Craig Cooper is a controller of this entity.
<b>Date of change</b>	27 June 2025
<b>No. of securities held prior to change</b>	<p><u>Direct Interests</u></p> <ul style="list-style-type: none"> <li>2,000,000 Performance Rights expiring 30 November 2027</li> <li>7,500,000 Performance Rights expiring 9 May 2030</li> <li>11,509,863 FPO</li> <li>3,303,288 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <p><u>C2 Ventures Pty Ltd</u></p> <ul style="list-style-type: none"> <li>122,776,955 FPO</li> <li>1,500,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026</li> <li>32,417,520 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul>

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	As above
<b>Number acquired</b>	<u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>45,694,239 FPO Shares at \$0.04 per share under the Entitlement Offer (including sub-underwriting)</li> </ul>
<b>Number disposed</b>	NIL
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<b>Acquired</b>  All Fully Paid Ordinary Shares were issued for \$0.04 per share cash consideration as per the non-renounceable pro rata Entitlement offer announced to the ASX on 6 June 2025.
<b>No. of securities held after change</b>	<u>Direct Interests</u> <ul style="list-style-type: none"> <li>2,000,000 Performance Rights expiring 30 November 2027</li> <li>7,500,000 Performance Rights expiring 9 May 2030</li> <li>11,509,863 FPO</li> <li>3,303,288 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <u>C2 Ventures Pty Ltd</u> <ul style="list-style-type: none"> <li>168,471,194 FPO</li> <li>1,500,000 Convertible Note Options exercisable at \$0.45 each, expiring 31 August 2026</li> <li>32,417,520 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<b>Acquired</b>  Fully Paid Ordinary Shares issued in accordance with the non-renounceable pro rata Entitlement offer announced to the ASX on 6 June 2025.

---

+ See chapter 19 for defined terms.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A as no interest in contracts.
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.  
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	CARDIEX LIMITED
<b>ABN</b>	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Charlie Taylor
<b>Date of last notice</b>	14 May 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<u>CW Taylor Family Trust</u>  Charlie Taylor is a controller and beneficiary of this entity.
<b>Date of change</b>	27 June 2025
<b>No. of securities held prior to change</b>	<u>Direct</u> <ul style="list-style-type: none"> <li>1,000,000 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <u>Indirect</u> CW Taylor Family Trust <ul style="list-style-type: none"> <li>833,334 Fully Paid Ordinary Shares</li> <li>833,334 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul>
<b>Class</b>	As above
<b>Number acquired</b>	CW Taylor Family Trust <ul style="list-style-type: none"> <li>208,334 Fully Paid Ordinary Shares at \$0.04 per share under the Entitlement Offer</li> </ul>



**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Number disposed</b>	NIL
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<b>Acquired</b> All Fully Paid Ordinary Shares were issued for \$0.04 per share cash consideration as per the non-renounceable pro rata Entitlement offer announced to the ASX on 6 June 2025.
<b>No. of securities held after change</b>	<u>Direct</u> <ul style="list-style-type: none"> <li>1,000,000 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul> <u>Indirect</u> CW Taylor Family Trust <ul style="list-style-type: none"> <li>1,041,668 FPO</li> <li>833,334 Quoted Options at \$0.20 expiring 30 November 2025</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<b>Acquired</b> Fully Paid Ordinary Shares issued in accordance with the non-renounceable pro rata Entitlement offer announced to the ASX on 6 June 2025.

---

+ See chapter 19 for defined terms.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A as no interest in contracts.
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.